Video

Dr. Neal Shore on the future of darolutamide in prostate cancer

Author(s):

Urology Times staff
Conference|GU Cancers Symposium

Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Neal D. Shore, MD, medical director of the Carolina Urologic Research Center, highlights the next steps for darolutamide (Nubeqa) in prostate cancer. The FDA approved the androgen receptor pathway inhibitor in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

Related Videos
Related Content
Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
May 5th 2025

AUA 2025 recap: Urologic oncology trials in progress

Hannah Clarke
Take a look through some of the notable studies that were spotlighted during this year’s meeting.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
May 2nd 2025

TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

Hannah Clarke
Data showed an overall CR rate of 82.4%.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
© 2025 MJH Life Sciences

All rights reserved.